Michele Provenzano1, Maria Jesús Puchades2, Carlo Garofalo1, Niels Jongs3, Luis D'Marco4, Michele Andreucci5, Luca De Nicola1, Jose Luis Gorriz2, Hiddo J L Heerspink. 1. Division of Nephrology, University of Campania "Luigi Vanvitelli," Naples, Italy. 2. Nephrology Service, Clinic University hospital, INCLIVA Health Research Institute, University of Valencia, Valencia, Spain. 3. Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. 4. Universidad Cardenal Herrera-CEU, CEU Universities, Valencia, Spain. 5. Department of Health Sciences, Magna Graecia University of Catanzaro, Catanzaro, Italy.
Abstract
BACKGROUND: Sodium glucose cotransporter 2 (SGLT2) inhibitors and mineralocorticoid receptor antagonists (MRAs) reduce the urinary albumin-to-creatinine ratio (UACR) and confer kidney and cardiovascular protection in patients with CKD. We assessed efficacy and safety of the SGLT2 inhibitor dapagliflozin and MRA eplerenone alone and in combination in patients with CKD. METHODS: We conducted a randomized open-label crossover trial in patients with urinary albumin excretion ≥100 mg/24 hr, eGFR 30-90 ml/min per 1.73 m2, who had been receiving maximum tolerated stable doses of an ACE inhibitor (ACEi) or angiotensin receptor blocker (ARB). Patients were assigned to 4-week treatment periods with dapagliflozin 10 mg/day, eplerenone 50 mg/day, or their combination in random order, separated by 4-week washout periods. Primary outcome was the correlation in UACR changes between treatments. Secondary outcome was the percent change in 24-hour UACR from baseline. RESULTS: Of 57 patients screened, 46 were randomly assigned (mean eGFR, 58.1 ml/min per 1.73 m2; median UACR, 401 mg/g) to the three groups. Mean percentage change from baseline in UACR after 4 weeks of treatment with dapagliflozin, eplerenone, and dapagliflozin-eplerenone was -19.6% (95% confidence interval [CI], -34.3 to -1.5), -33.7% (95% CI, -46.1 to -18.5), and -53% (95% CI, -61.7 to -42.4; P<0.001 versus dapagliflozin; P=0.01 versus eplerenone). UACR change during dapagliflozin or eplerenone treatment did not correlate with UACR change during dapagliflozin-eplerenone (r=-0.13; P=0.47; r=-0.08; P=0.66, respectively). Hyperkalemia was more frequently reported with eplerenone (n=8; 17.4%) compared with dapagliflozin (n=0; 0%) or dapagliflozin-eplerenone (n=2; 4.3%; P between-groups=0.003). CONCLUSIONS: Albuminuria changes in response to dapagliflozin and eplerenone did not correlate, supporting systematic rotation of these therapies to optimize treatment. Combining dapagliflozin with eplerenone resulted in a robust additive UACR-lowering effect. A larger trial in this population is required to confirm long-term efficacy and safety of combined SGLT2 inhibitor and MRA treatment. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: European Union Clinical Trials Register, EU 2017-004641-25.
BACKGROUND: Sodium glucose cotransporter 2 (SGLT2) inhibitors and mineralocorticoid receptor antagonists (MRAs) reduce the urinary albumin-to-creatinine ratio (UACR) and confer kidney and cardiovascular protection in patients with CKD. We assessed efficacy and safety of the SGLT2 inhibitor dapagliflozin and MRA eplerenone alone and in combination in patients with CKD. METHODS: We conducted a randomized open-label crossover trial in patients with urinary albumin excretion ≥100 mg/24 hr, eGFR 30-90 ml/min per 1.73 m2, who had been receiving maximum tolerated stable doses of an ACE inhibitor (ACEi) or angiotensin receptor blocker (ARB). Patients were assigned to 4-week treatment periods with dapagliflozin 10 mg/day, eplerenone 50 mg/day, or their combination in random order, separated by 4-week washout periods. Primary outcome was the correlation in UACR changes between treatments. Secondary outcome was the percent change in 24-hour UACR from baseline. RESULTS: Of 57 patients screened, 46 were randomly assigned (mean eGFR, 58.1 ml/min per 1.73 m2; median UACR, 401 mg/g) to the three groups. Mean percentage change from baseline in UACR after 4 weeks of treatment with dapagliflozin, eplerenone, and dapagliflozin-eplerenone was -19.6% (95% confidence interval [CI], -34.3 to -1.5), -33.7% (95% CI, -46.1 to -18.5), and -53% (95% CI, -61.7 to -42.4; P<0.001 versus dapagliflozin; P=0.01 versus eplerenone). UACR change during dapagliflozin or eplerenone treatment did not correlate with UACR change during dapagliflozin-eplerenone (r=-0.13; P=0.47; r=-0.08; P=0.66, respectively). Hyperkalemia was more frequently reported with eplerenone (n=8; 17.4%) compared with dapagliflozin (n=0; 0%) or dapagliflozin-eplerenone (n=2; 4.3%; P between-groups=0.003). CONCLUSIONS: Albuminuria changes in response to dapagliflozin and eplerenone did not correlate, supporting systematic rotation of these therapies to optimize treatment. Combining dapagliflozin with eplerenone resulted in a robust additive UACR-lowering effect. A larger trial in this population is required to confirm long-term efficacy and safety of combined SGLT2 inhibitor and MRA treatment. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: European Union Clinical Trials Register, EU 2017-004641-25.
Authors: Carol Pollock; Bergur Stefánsson; Daniel Reyner; Peter Rossing; C David Sjöström; David C Wheeler; Anna Maria Langkilde; Hiddo J L Heerspink Journal: Lancet Diabetes Endocrinol Date: 2019-04-13 Impact factor: 32.069
Authors: Vlado Perkovic; Meg J Jardine; Bruce Neal; Severine Bompoint; Hiddo J L Heerspink; David M Charytan; Robert Edwards; Rajiv Agarwal; George Bakris; Scott Bull; Christopher P Cannon; George Capuano; Pei-Ling Chu; Dick de Zeeuw; Tom Greene; Adeera Levin; Carol Pollock; David C Wheeler; Yshai Yavin; Hong Zhang; Bernard Zinman; Gary Meininger; Barry M Brenner; Kenneth W Mahaffey Journal: N Engl J Med Date: 2019-04-14 Impact factor: 91.245
Authors: Rajiv Agarwal; Amer Joseph; Stefan D Anker; Gerasimos Filippatos; Peter Rossing; Luis M Ruilope; Bertram Pitt; Peter Kolkhof; Charlie Scott; Robert Lawatscheck; Daniel J Wilson; George L Bakris Journal: J Am Soc Nephrol Date: 2021-11-03 Impact factor: 10.121
Authors: Uzma F Mehdi; Beverley Adams-Huet; Philip Raskin; Gloria L Vega; Robert D Toto Journal: J Am Soc Nephrol Date: 2009-11-19 Impact factor: 10.121
Authors: Hiddo J L Heerspink; Bergur V Stefánsson; Ricardo Correa-Rotter; Glenn M Chertow; Tom Greene; Fan-Fan Hou; Johannes F E Mann; John J V McMurray; Magnus Lindberg; Peter Rossing; C David Sjöström; Roberto D Toto; Anna-Maria Langkilde; David C Wheeler Journal: N Engl J Med Date: 2020-09-24 Impact factor: 91.245
Authors: Murray Epstein; Gordon H Williams; Myron Weinberger; Andrew Lewin; Scott Krause; Robin Mukherjee; Rajiv Patni; Bruce Beckerman Journal: Clin J Am Soc Nephrol Date: 2006-07-19 Impact factor: 8.237
Authors: Megumi Oshima; Brendon L Neuen; JingWei Li; Vlado Perkovic; David M Charytan; Dick de Zeeuw; Robert Edwards; Tom Greene; Adeera Levin; Kenneth W Mahaffey; Luca De Nicola; Carol Pollock; Norman Rosenthal; David C Wheeler; Meg J Jardine; Hiddo J L Heerspink Journal: J Am Soc Nephrol Date: 2020-09-30 Impact factor: 10.121
Authors: George L Bakris; Rajiv Agarwal; Stefan D Anker; Bertram Pitt; Luis M Ruilope; Peter Rossing; Peter Kolkhof; Christina Nowack; Patrick Schloemer; Amer Joseph; Gerasimos Filippatos Journal: N Engl J Med Date: 2020-10-23 Impact factor: 91.245
Authors: Peter Kolkhof; Elke Hartmann; Alexius Freyberger; Mira Pavkovic; Ilka Mathar; Peter Sandner; Karoline Droebner; Amer Joseph; Jörg Hüser; Frank Eitner Journal: Am J Nephrol Date: 2021-06-10 Impact factor: 3.754